Abstract |
Community-acquired pneumonia (CAP) is the leading cause of death due to bacterial infection. It accounts for 10 million physician office visits in the USA annually. However, 80% of these are managed in the community, usually with oral antibiotic therapy. Typically, such courses have lasted 10 days or longer. Streptococcus pneumoniae accounts for 25% of all CAP infections; resistance among S. pneumoniae to all classes of antibiotics, including fluoroquinolones, poses new and shifting challenges to the primary care physician. Gemifloxacin is a potent agent, active against pneumococci and atypical pathogens. Administered once daily for 5 days, gemifloxacin is highly efficacious and well tolerated. Gemifloxacin administered for 5-7 days is a cost effective and safe alternative to both parenteral and oral antimicrobials, which may not cover the emerging resistant respiratory pathogens.
|
Authors | Glenn S Tillotson |
Journal | Expert review of anti-infective therapy
(Expert Rev Anti Infect Ther)
Vol. 6
Issue 4
Pg. 405-18
(Aug 2008)
ISSN: 1744-8336 [Electronic] England |
PMID | 18662107
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Bacterial Agents
- Fluoroquinolones
- Naphthyridines
- Gemifloxacin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Community-Acquired Infections
(drug therapy, economics, epidemiology)
- Drug Resistance, Bacterial
- Fluoroquinolones
(therapeutic use)
- Gemifloxacin
- Humans
- Naphthyridines
(therapeutic use)
- Pneumonia, Bacterial
(drug therapy, economics, epidemiology)
|